ArticleBritish journal of cancer2005
Aberrant methylation of SPARC in human lung cancers.
Article in British journal of cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 77 citations in OpenAlex.
- Pre-diagnostic Demographic, Lifestyle, and Health History Factors in Association with Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression in Colorectal Cancer Tissue.Biomarker insights · 2025Article
- Cell-type-specific alternative polyadenylation as a therapeutic biomarker in lung cancer progression.Molecular therapy. Nucleic acids · 2023Article
- Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression.Molecular therapy. Nucleic acids · 2023Article
- Modeling extracellular matrix through histo-molecular gradient in NSCLC for clinical decisions.Frontiers in oncology · 2022Article
- Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1.Investigational new drugs · 2017Article
- A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors.Oncotarget · 2017Article
- Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.Molecular and clinical oncology · 2017Article
- SPARC Promotes Cell Invasion In Vivo by Decreasing Type IV Collagen Levels in the Basement Membrane.PLoS genetics · 2016Article
- Epigenetics of lung cancer.Translational research : the journal of laboratory and clinical medicine · 2015Review
- Revisiting the matricellular concept.Matrix biology : journal of the International Society for Matrix Biology · 2014Review
- First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.International journal of nanomedicine · 2014Review
- Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?Haematologica · 2013Review
- [Correlation of KLF4 and SPARC expression with the clinical characteristics of non-small cell lung cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2012Article
- Aberrant methylation of SPARC in human hepatocellular carcinoma and its clinical implication.World journal of gastroenterology · 2012Article
- Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Article
- Article
- Anti-cancer role of SPARC, an inhibitor of adipogenesis.Cancer treatment reviews · 2011Review
- Aberrant methylation of secreted protein, acidic and rich in cysteine in human laryngeal and hypopharyngeal carcinoma.Oncology letters · 2011Article
- SPARC gene expression is repressed in human urothelial cells (UROtsa) exposed to or malignantly transformed by cadmium or arsenite.Toxicology letters · 2010Article
- Demethylating Agents in the Treatment of Cancer.Pharmaceuticals (Basel, Switzerland) · 2010Review
Corrections and comments
- Retraction · 2013-02-19Duplication of Data · Investigation by Company/Institution · Misconduct by Author ·
- Commented on by
- Commented on by
- Retracted
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
SPARC (secreted protein acidic and rich in cysteine) is an extracellular Ca2+-binding matricellular glycoprotein associated with the regulation of cell adhesion and growth. We investigated loss of expression of SPARC gene and promoter methylation in lung cancers and correlated the data with clinicopathological features. We observed loss of SPARC expression in 12 of 20 (60%) lung cancer cell lines. Treatment of expression-negative cell lines with a demethylating agent restored expression in all cases. Methylation frequencies of SPARC gene were 55% in 20 lung cancer cell lines. Primary tumours had methylation at a rate of 69% (119 of 173), while nonmalignant lung tissues (n=60) had very low rates (3%). In lung adenocarcinomas, SPARC methylation correlated with a negative prognosis (P=0.0021; relative risk 4.65, 95% confidence interval 1.75-12.35, multivariate Cox's proportional-hazard model). Immunostaining revealed protein expression in bronchial epithelium (weak intensity) and in juxtatumoral stromal tissues (strong intensity) accompanied by frequent loss in cancer cells that correlated with the presence of methylation (P<0.001). Our findings are of biological interest and potentially of clinical importance in human lung cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.